Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Revolution Medicines (42Z) Drug Pipeline

17 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Gemcitabine, Nab-Paclitaxel, Daraxonrasib, ZoldonrasibPancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pdac, Pancreatic Ductal Adenocarcinoma (Pdac), Pancreatic Cancer Metastatic, Pdac - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenosquamous CarcinomaPhase IIIRecruitingStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaSep 01, 2026―
Pembrolizumab, Zoldonrasib, Pemetrexed + Cisplatin /CarboplatinNon-small Cell Lung Cancer, Nsclc, Non-Small Cell Lung Cancer Nsclc, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Lung Cancer (Nsclc), Non-Squamous Non Small Cell Lung Cancer, Metastatic Nsclc - Non-Small Cell Lung CancerPhase IIIRecruitingStudy of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCAug 17, 2026
Leucovorin, Oxaliplatin, Gemcitabine, 5-Fluorouracil, Irinotecan, Nab-Paclitaxel, ZoldonrasibPancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pdac, Pancreatic Ductal Adenocarcinoma (Pdac), Pancreatic Cancer Metastatic, Pdac - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenosquamous CarcinomaPhase IIIRecruitingStudy of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )May 26, 2026
Nab-Paclitaxel, Gemcitabine, DaraxonrasibPancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pdac, Pancreatic Ductal Adenocarcinoma (Pdac), Pancreatic Cancer Metastatic, Pdac - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenosquamous CarcinomaPhase IIIRecruitingStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaMar 10, 2026
Cetuximab, Daraxonrasib, Ivonescimab, Elironrasib, Zoldonrasib, Carboplatin/Cisplatin + PemetrexedAdvanced Solid Tumors, Non-Small Cell Lung Cancer (Nsclc), Nsclc, Metastatic Solid Tumors, Colorectal Cancer (Crc), Crcphase1AndPhase2RecruitingStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsFeb 02, 2026
Cetuximab, Daraxonrasib, Rmc-5127Pancreatic Cancer, Advanced Solid Tumors, Non-Small Cell Lung Cancer (Nsclc), Nsclc, Pancreatic Adenocarcinoma, Colorectal Cancer (Crc), Pdac, Crc, Pancreatic Ductal Adenocarcinoma (Pdac), Lung Cancer (Nsclc)Phase IRecruitingStudy of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsJan 09, 2026
DaraxonrasibPancreatic Cancer, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (Pdac), Resected Pancreatic AdenocarcinomaPhase IIIRecruitingStudy of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Nov 13, 2025
Rmc-6236, Tng462, Rmc-9805Pancreatic Cancer Metastatic, Lung Cancer, Nsclc, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma, Ras Mutation, Mtap Deletion, Thoracic Cancerphase1AndPhase2RecruitingStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsMar 28, 2025
Docetaxel, DaraxonrasibNon-small Cell Lung Cancer, Nsclc, Nsclc (Non-Small Cell Lung Cancer), Nsclc (Advanced Non-Small Cell Lung Cancer), Nsclc (Non-Small Cell Lung Carcinoma)Phase IIIRecruitingStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Mar 10, 2025
Gemcitabine, Nab-Paclitaxel, Oxaliplatin, Irinotecan, Rmc-6236, Leucovorin, 5-Fluorouracil, Liposomal IrinotecanPancreatic Cancer, Pdac, Pdac - Pancreatic Ductal AdenocarcinomaPhase IIIRecruitingPhase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Sep 20, 2024

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Revolution Medicines, Inc. (DE:42Z) have in its pipeline
Revolution Medicines DE:42Z is currently developing the following drugs: Gemcitabine, Nab-Paclitaxel, Daraxonrasib, Zoldonrasib, Pembrolizumab, Zoldonrasib, Pemetrexed + Cisplatin /Carboplatin, Leucovorin, Oxaliplatin, Gemcitabine, 5-Fluorouracil, Irinotecan, Nab-Paclitaxel, Zoldonrasib, Nab-Paclitaxel, Gemcitabine, Daraxonrasib, Cetuximab, Daraxonrasib, Ivonescimab, Elironrasib, Zoldonrasib, Carboplatin/Cisplatin + Pemetrexed, Cetuximab, Daraxonrasib, Rmc-5127, Daraxonrasib, Rmc-6236, Tng462, Rmc-9805, Docetaxel, Daraxonrasib, Gemcitabine, Nab-Paclitaxel, Oxaliplatin, Irinotecan, Rmc-6236, Leucovorin, 5-Fluorouracil, Liposomal Irinotecan, Gemcitabine, Bevacizumab, Nab-Paclitaxel, Rmc-6236, Cetuximab, Rmc-9805, Mfolfox6 Regimen, Mfolfirinox Regimen, Pembrolizumab, Rmc-6291, Pemetrexed, Rmc-6236, Carboplatin, Cisplatin, Rmc-9805, Assigned Interventions, Rmc-6236, Rmc-9805, Rmc-6291, Rmc-6236, Rmc-5552. These drug candidates are in various stages of clinical development as the company works toward FDA approval.